Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 6807-6815

  Schnell, Gretja ^a   Tripathi, Rakesh ^a   Beyer, Jill ^a   Reisch, Thomas ^a   Krishnan, Preethi ^a   Lu, Liangjun ^a   Dekhtyar, Tatyana ^a   Hall, Coleen ^a   Vilchez, Regis A ^a   Pilot Matias, Tami ^a   Collins, Christine ^a  

^a ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; ABT-267; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; RITONAVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG TREATMENT FAILURE; FEMALE; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; MALE; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; ADULT; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PATHOGENICITY; PHASE 2 CLINICAL TRIAL; VIROLOGY; YOUNG ADULT;

ADULT; ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; PHYLOGENY; RITONAVIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946213210     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01229-15     Document Type: Article

References (39)

1. Abdel-Hamid M., El-Daly M, Molnegren V., El-Kafrawy S, Abdel-Latif S, Esmat G., Strickland GT, Loffredo C, Albert J, Widell A. 2007. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol 88:1526-1531. http://dx.doi.org/10.1099/vir.0.82626-0.
2. WHO. 2014. Hepatitis C: fact sheet no. 164. World Health Organization, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs164/en/.
3. Smith DB, Bukh J, Kuiken C., Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource. Hepatology 59:318-327. http://dx.doi.org/10.1002/hep.26744.
4. Gower E, Estes C, Blach S., Razavi-Shearer K, Razavi H. 2014. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45-S57. http://dx.doi.org/10.1016/j.jhep.2014.07.027.
5. Kamal SM. 2007. Improving outcome in patients with hepatitis C virus genotype4. Am J Gastroenterol 102:2582-2588. http://dx.doi.org/10.1111/j.1572-0241.2007.01538.x.
6. Kamal SM, Nasser IA 2008. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 47:1371-1383. http://dx.doi.org/10.1002/hep.22127.
7. Di Lello F.A., Neukam K, Parra-Sanchez M, Plaza Z., Soriano V, Cifuentes C, Mira J.A., Poveda E., Pineda JA. 2013. Hepatitis C virus genotype 4 in southern and central Spain does not originate from recent foreign migration waves. J Med Virol 85:1734-1740. http://dx.doi.org/10.1002/jmv.23657.
8. Afdhal N, Reddy KR, Nelson D.R., Lawitz E., Gordon SC, Schiff E, Nahass R, Ghalib R., Gitlin N, Herring R, Lalezari J., Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P, ION-2 Investigators. 2014. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:1483-1493. http://dx.doi.org/10.1056/NEJMoa1316366.
9. Afdhal N, Zeuzem S, Kwo P., Chojkier M, Gitlin N, Puoti M., Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P., Foster GR, Brau N, Buti M, Jacobson I.M., Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, ION-1 Investigators. 2014. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370:1889-1898. http://dx.doi.org/10.1056/NEJMoa1402454.
10. Feld JJ, Kowdley KV, Coakley E, Sigal S., Nelson DR, Crawford D, Weiland O, Aguilar H., Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L., Podsadecki T, Bernstein B. 2014. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370: 1594-1603. http://dx.doi.org/10.1056/NEJMoa1315722.
11. Kowdley KV, Gordon SC, Reddy K.R., Rossaro L., Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R., Ryan M, Rustgi V, Chojkier M., Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW, ION-3 Investigators. 2014. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370:1879-1888. http://dx.doi.org/10.1056/NEJMoa1402355.
12. Zeuzem S, Jacobson IM, Baykal T, Marinho R.T., Poordad F., Bourliere M, Sulkowski MS, Wedemeyer H, Tam E., Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J., Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. 2014. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370:1604-1614. http://dx.doi.org/10.1056/NEJMoa1401561.
13. Hézode C., Hirschfield GM, Ghesquiere W, Sievert W., Rodriguez-Torres M, Shafran SD, Thuluvath P.J., Tatum HA, Waked I, Esmat G, Lawitz E.J., Rustgi VK, Pol S, Weis N, Pockros P.J., Bourliere M., Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Brau N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S. 2014. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut http://dx.doi.org/10.1136/gutjnl-2014-307498.
14. Lawitz E, Mangia A, Wyles D., Rodriguez-Torres M, Hassanein T, Gordon S.C., Schultz M., Davis MN, Kayali Z, Reddy KR, Jacobson I.M., Kowdley KV, Nyberg L, Subramanian GM, Hyland R.H., Arterburn S., Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. 2013. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368:1878-1887. http://dx.doi.org/10.1056/NEJMoa1214853.
15. Zeuzem S, Dusheiko GM, Salupere R, Mangia A., Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E., Brainard DM, Symonds WT, Subramanian GM, McHutchison J.G., Weiland O., Reesink HW, Ferenci P, Hezode C, Esteban R., VALENCE Investigators. 2014. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370:1993-2001. http://dx.doi.org/10.1056/NEJMoa1316145.
16. DeGoey DA, Randolph JT, Liu D, Pratt J., Hutchins C, Donner P, Krueger A.C., Matulenko M., Patel S, Motter CE, Nelson L, Keddy R., Tufano M, Caspi DD, Krishnan P, Mistry N., Koev G, Reisch TJ, Mondal R, Pilot-Matias T, Gao Y, Beno DW, Maring CJ, Molla A, Dumas E, Campbell A, Williams L, Collins C, Wagner R, Kati WM. 2014. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem 57:2047-2057. http://dx.doi.org/10.1021/jm401398x.
17. Menon RM, Klein CE, Lawal A.A., Chiu YL, Awni WM, Podsadecki TJ, Nada A, Bernstein BM 2009. Pharmacokinetics and tolerability of the HCV protease inhibitor ABT-450 following single ascending doses in healthy adult volunteers with and without ritonavir. Global Antiviral J 5:53.
18. Krishnan P, Beyer J, Mistry N., Koev G, Reisch T, DeGoey D., Kati W, Campbell A, Williams L., Xie W, Setze C, Molla A., Collins C, Pilot-Matias T. 2015. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C Virus NS5A. Antimicrob Agents Chemother 59:979-987. http://dx.doi.org/10.1128/AAC.04226-14.
19. Pilot-Matias T., Tripathi R, Cohen D., Gaultier I, Dekhtyar T, Lu L., Reisch T, Irvin M, Hopkins T., Pithawalla R, Middleton T, Ng T., McDaniel K, Or YS, Menon R, Kempf D, Molla A, Collins C. 2015. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 59:988-997. http://dx.doi.org/10.1128/AAC.04227-14.
20. Hézode C., Asselah T, Reddy K.R., Hassanein T., Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C., Schnell G, Pilot-Matias T, Mobashery N, Redman R., Vilchez RA, Pol S. 2015. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirinin treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomized, open-label trial. Lancet 385:2502-2509. http://dx.doi.org/10.1016/S0140-6736(15)60159-3.
21. Koletzki D, Dumont S, Vermeiren H., Fevery B, De Smet P, Stuyver LJ. 2010. Development and evaluation of an automated hepatitis C virus NS5B sequence-based subtyping assay. Clin Chem Lab Med 48:1095-1102.
22. Katoh K, Asimenos G, Toh H. 2009. Multiple alignment of DNA sequences with MAFFT. Methods Mol Biol 537:39-64. http://dx.doi.org/10.1007/978-1-59745-251-9-3.
23. Saitou N, Nei M. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4:406-425.
24. Studier JA, Keppler KJ 1988. A note on the neighbor-joining algorithm of Saitou and Nei. Mol Biol Evol 5:729-731.
25. Hasegawa M, Kishino H, Yano T. 1985. Dating of the human-ape splitting by a molecular clock of mitochondrial DNA. J Mol Evol 22:160-174. http://dx.doi.org/10.1007/BF02101694.
26. Kearse M, Moir R, Wilson A., Stones-Havas S, Cheung M, Sturrock S., Buxton S, Cooper A, Markowitz S., Duran C, Thierer T, Ashton B., Meintjes P, Drummond A. 2012. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 28:1647-1649. http://dx.doi.org/10.1093/bioinformatics/bts199.
27. Tamura K, Peterson D, Peterson N., Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731-2739. http://dx.doi.org/10.1093/molbev/msr121.
28. Tripathi RL, Krishnan P, He Y., Middleton T, Pilot-Matias T, Chen CM, Lau D.T., Lemon SM, Mo H, Kati W, Molla A. 2007. Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera. Antiviral Res 73:40-49. http://dx.doi.org/10.1016/j.antiviral.2006.07.005.
29. Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C., Razer A, Lefrere JJ, Pawlotsky J.M., De Micco P, Laperche S. 2007. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 45:1140-1145. http://dx.doi.org/10.1128/JCM.01982-06.
30. Avó AP, Agua-Doce I, Andrade A, Pádua E. 2013. Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay. J Med Virol 85:815-822. http://dx.doi.org/10.1002/jmv.23545.
31. Cai Q, Zhao Z, Liu Y., Shao X, Gao Z. 2013. Comparison of three different HCV genotyping methods: core, NS5B sequence analysis and line probe assay. Int J Mol Med 31:347-352.
32. Guelfo JR, Macias J, Neukam K., Di Lello FA, Mira JA, Merchante N, Mancebo M, Nunez-Torres R, Pineda J.A., Real LM. 2014. Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment. J Clin Microbiol 52:4027-4029. http://dx.doi.org/10.1128/JCM.02209-14.
33. Morice Y, Roulot D, Grando V., Stirnemann J, Gault E, Jeantils V., Bentata M, Jarrousse B, Lortholary O., Pallier C, Deny P. 2001. Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns. J Gen Virol 82:1001-1012.
34. Panasiuk A, Flisiak R, Mozer-Lisewska I, Adamek A., Tyczyno M, Halota W, Pawlowska M., Stanczak J, Berak H, Wawrzynowicz-Syczewska M, Boron-Kaczmarska A, Lapinski TW, Grzeszczuk A, Piekarska A., Tomasiewicz K, Jablkowski M, Kryczka W, Zarebska-Michaluk D, Stepien P, Garlicki AM, Kozlowska J, Wiercinska-Drapalo A, Zasik E, Mazur W, Dobracka B, Dobracki W, Simon K, Ryzko J, Pawlowska J, Dzierzanowska-Fangrat K, Januszkiewicz-Lewandowska D, Szenborn L, Zaleska I, Rokitka M, Strawinska E, Balinowska K, Smiatacz T, Stalke P, Sikorska K, Lakomy A, Zdrojewski M, Lachowicz A. 2013. Distribution of HCV genotypes in Poland. Przegl Epidemiol 67:11-16, 99-103.
35. Flisiak R, Halota W, Horban A., Juszczyk J, Pawlowska M, Simon K. 2011. Prevalence and risk factors of HCV infection in Poland. Eur J Gastroenterol Hepatol 23:1213-1217. http://dx.doi.org/10.1097/MEG.0b013e32834d173c.
36. Cantaloube JF, Gallian P, Laperche S., Elghouzzi MH, Piquet Y, Bouchardeau F, Jordier F., Biagini P, Attoui H, de Micco P. 2008. Molecular characterization ofgenotype2 and4 hepatitisC virus isolates in French blood donors. J Med Virol 80:1732-1739. http://dx.doi.org/10.1002/jmv.21285.
37. Esmat GE, Shiha G, Omar R.F., Hassany M., Hammad R, Khairy M, Samir W., Soliman R, Brainard DM, Jiang D, Kersey K., Knox SJ, Massetto B, McHutchison JG, Doss WH 2014. Sofosbuvir plus ribavirin in the treatment of Egyptian patients with chronic genotype 4 HCV infection. Hepatology 60:662A-663A.
38. Ruane PJ, Ain D, Stryker R., Meshrekey R, Soliman M, Wolfe P.R., Riad J., Mikhail S, Kersey K, Jiang D., Massetto B, Doehle B, Kirby B.J., Knox SJ, McHutchison JG, Symonds WT. 2014. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol http://dx.doi.org/10.1016/j.jhep.2014.10.044.
39. Hassanein T, Sims KD, Bennett M, Gitlin N., Lawitz E, Nguyen T, Webster L., Younossi Z, Schwartz H, Thuluvath P.J., Zhou H., Rege B, McPhee F, Zhou N., Wind-Rotolo M, Chung E, Griffies A, Grasela DM, Gardiner DF. 2015. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol http://dx.doi.org/10.1016/j.jhep.2014.12.025.